Biogen Idec,a big pharma company has entered into a pharma partners research collaboration with premier academic and research institutions to sequence the genomes of up to 1,000 patients with amyotrophic lateral sclerosis in an effort to gain a deeper understanding about the fundamental genetic causes of ALS.
Under the terms of the pharma partners agreements, Biogen Idec will fund the project at the laboratories of David Goldstein, Ph.D., Director of the Center for Human Genome Variation at Duke University, and Richard M. Myers, Ph.D., President and Director of the HudsonAlpha Institute for Biotechnology.
Along with Dr. Goldstein and Dr. Myers, the pharma partners consortium will include Robert Brown, D.Phil., M.D., a neurologist at the University of Massachusetts Medical School who has devoted his career to identify gene mutations that cause ALS; Aaron Gitler, Ph.D., a geneticist at Stanford University whose recent work has focused on risk factors associated with ALS; Tom Maniatis, Ph.D., a molecular biologist at Columbia University studying changes in gene expression associated with ALS; Guy Rouleau, MD, Ph.D., a neuro-geneticist at the University of Montreal with expertise in gene identification in multiple neurological diseases; and Neil Shneider, M.D., Ph.D., a neurologist and neuroscientist in the Motor Neuron Center at Columbia University, whose work focuses on mechanisms of motor neuron degeneration in ALS.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity